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The Dichotomous Responses Driven
by β-Defensins
Jennifer R. Shelley, Donald J. Davidson and Julia R. Dorin*
Centre for Inflammation Research, The University of Edinburgh, Edinburgh BioQuarter, Edinburgh, Scotland
Defensins are short, rapidly evolving, cationic antimicrobial host defence peptides with
a repertoire of functions, still incompletely realised, that extends beyond direct microbial
killing. They are released or secreted at epithelial surfaces, and in some cases, from
immune cells in response to infection and inflammation. Defensins have been described
as endogenous alarmins, alerting the body to danger and responding to inflammatory
signals by promoting both local innate and adaptive systemic immune responses.
However, there is now increasing evidence that they exert variable control on the
response to danger; creating a dichotomous response that can suppress inflammation
in some circumstances but exacerbate the response to danger and damage in others
and, at higher levels, lead to a cytotoxic effect. Focussing in this review on human
β-defensins, we discuss the evidence for their functions as proinflammatory, immune
activators amplifying the response to infection or damage signals and/or as mediators of
resolution of damage, contributing to a return to homeostasis. Finally, we consider their
involvement in the development of autoimmune diseases.
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INTRODUCTION
Defensins and defensin-like peptides are found throughout multicellular organisms including
plants, insects and fungi, as well as vertebrates. They were first described as antimicrobial peptides
(AMP), with the ability to rapidly penetrate and disrupt the outermembrane of bacteria, viruses and
fungi to varying degrees and subsequently disrupt metabolic processes within (1). It is appealing
to consider that this innate, protective mechanism is so fundamental that the defensin genes
have been evolutionarily conserved for this purpose. In fact, the value of the structure of these
disulphide-stabilised, cysteine containing, positively charged loop peptides has resulted in two
evolutionarily distinct defensin families that have arisen separately by convergent evolution (2). The
cis-defensin superfamily (present in insects, fungi and plants), has the central beta-strand stabilised
by disulphide bridges, connected to the same alpha-helix in the “cis” orientation. This is in contrast
to the vertebrate (and some invertebrate) defensins, in which the central beta strand has disulphide
bridges that stabilise structures in non-cis or “trans” orientations (3, 4). Both cis and trans families
have undergone rapid expansion and evolutionary change to reveal a repertoire of diverse functions
that are only recently becoming clear (5).
Here we focus on the human, trans-defensins—specifically β-defensins. We discuss their role(s)
in host defence other than by direct microbial killing. We consider whether the function of these
molecules is purely as an acute “alarmin”-type response to danger/damage (alerting the body and
promoting both local innate, and also local and systemic adaptive immune responses), or if they
are also instrumental in controlling inflammation (limiting the damage response and mediating
resolution)—thus speeding a return to homeostasis.
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BETA-DEFENSIN BACKGROUND
The defensin family is a large, multigene family that is rapidly
changing and evolving. In humans there are two functional
subfamilies of defensins (α and β) which differ in their cysteine
connections but retain the central structure of a trans-defensin
cysteine knot. Both α- and β- defensins are generally encoded
by two (sometimes three) exons, with the first exon containing
the hydrophobic, anionic leader sequence and the second exon
encoding the mature, cationic peptide. The α-defensins are
stored in this inactive form in the granules of either neutrophils
or intestinal Paneth cells, while β-defensins are expressed
predominantly in epithelial cells and believed to be cleaved by
signal peptidase as they are secreted (6).
β-defensins are an ancient family, from which the α-defensins
have evolved. The amino acid sequence of human β-defensins
is highly divergent, and has been subject to complex positive
and negative selection (7). During this process, other than
the cysteines, only a core glycine and aspartic acid are well-
conserved. β-Defensins have an identifiable consensus sequence
of X2−10CX5−7(G/A)XCX3−4CX9−13CX4−7CCXn and the three
disulphide connections following oxidation are assumed to be
the same for all β-defensins (CI—CV, CII—CIV, and CIII—CVI).
The highly variable residues in the mature peptide are rich in
the positively charged amino acids lysine and arginine to varying
degrees (7). Some of the peptides have extended peptide tails
with clusters of lysines and residues for additional potential
glycosylation sites (8). In the human genome there are five β-
defensin clusters located over three chromosomes, with around
33 genes, of which only a few have known function (9, 10) and
seven of which (in humans) are hyper copy number variable
(CNV) (5). The many gene duplications in the defensin family
result in gene “birth and death” and as the gene number and
sequence changes, some genes become specialised for a new
function; while at the species level, there are increased numbers
or complete loss of gene clades. Mice, for example, have different
numbers of cryptdins (intestinal α-defensins) even between
different strains of Mus domesticus (11) and no longer have
neutrophil expressed α-defensin genes. The sequence diversity
and gene number variation in the defensin genes is not surprising
as strain specific diverse regions (SSDR) between mouse strains
are highly enriched for genes involved in immunity, infection
and reproduction functions, all of which are associated with
defensins (12).
Gene duplication and sequence change, followed by selection
for advantageous changes, allows functional change of
paralogues. The structure of some off-shoots of the main
β-defensin tree has been so advantageous that there are examples
of both reptiles (snakes and lizards) and mammals (egg laying
platypus) independently giving rise to venom toxins, with
a variety of actions that include antimicrobial function (13)
and potassium channel blocking ability (14). Additionally,
Kudryashova et al. (15) showed that both α and β-human
defensins could target, destabilise and inactivate bacterial
protein toxins (16). This work implies that defensins may have
protective abilities that are not limited to microbe destruction.
Intriguingly, and perhaps indicative of roles of immunological
modulation/damage, the human defensin HBD2 has been shown
to bind to the outer pore domain of potassium channel Kv1.3 and
efficiently inhibit channel currents and suppress IL-2 production
in both human primary T cells and peripheral mononuclear
cells (17).
At this point, the expression pattern of β-defensins in humans
is worthy of mention [see useful reviews on this here (18, 19)]. All
the many β-defensin members are strongly expressed in various
segments of the epididymis post puberty (20, 21) and a major
function of β-defensins is in sperm maturation. A β-defensin
mutation in humanDEFB126was found to reduce spermmotility
and fertility in Chinese men (22). In addition, mice deleted
for several β-defensins (in pairs or more) are infertile and this
demonstrates their synergistic function in sperm maturation,
movement and protection against premature acrosome reaction
(23, 24). Sperm are rich in β-defensin in the glycocalyx of
the head and this may protect the sperm from inappropriate
activation. However, mice with transgenic over-expression of
an epidydimal specific β-defensin (orthologous to human β-
defensin SPAG11), while being resistant to E. coli infection,
simultaneously show reduced expression of inflammatory
cytokines IL-1α and IL-1β, indicating multiple functions and
implying immunomodulatory properties.
Expression of β-defensins is not just evident in the male
genitourinary system, as these peptides are also widely expressed
in other tissues. In this review we are focussing primarily
on HBD1–4, as these genes are the most studied in human.
Their peptide sequence, gene name and charge are given in
Table 1. HBD1–3 are found in the female reproductive tract
in endometrium, vagina and cervix, while HBD1 is found
in fallopian tubes (26). These defensins are increased in
expression at a number of sites in the body, including the
tracheal epithelium, gingival mucosa, respiratory epithelium,
gastrointestinal epithelium, genitourinary tract epithelium and
skin (27–30). In addition, HBD1 is produced constitutively
in a range of other epithelial tissues, including the small
intestine, pancreas, and kidney. Expression of HBD1 may also be
increased in various cell types following viral stimulation (31) and
both HBD2 and HBD3 are inducible proteins, with expression
occurring in various cell types in response to infection (32, 33),
proinflammatory cytokines (including IL-1β, IL-17,TNFα, and
IL-22) (34–36) and injury. The response to these inducers is not
the same for every gene or for every condition. For example,
plasma levels of β-defensins are variable in individuals with
asthmatic vs. normal airways, where HBD3 is elevated by HBD1
and 2 are reduced (37). HBD3 and HBD4 are significantly
increased, but HBD2 is decreased. The level of mouse DEFB14
was also increased in asthmatic animals. Expression may also be
varied by genomic copy number of DEFB103, DEFB4, DEFB104
but DEFB1 does not show copy number variation (CNV). Both
copy number and promoter sequence variation has been shown
to contribute to expression of DEFB4 and DEFB103 (38, 39), but
inflammatory stimuli can override these.
This widespread pattern of expression, and inducibility in
infection and inflammation, raises the question of what is
the principle function of these peptides? A number of studies
have been conducted addressing whether β-defensins act as
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TABLE 1 | Mature Peptide sequence of the four human β-defensins described most commonly in the literature.
PEPTIDE GENE Mature peptide sequence Charge
HBD1 DEFB1 DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK 4
HBD2 DEFB4 GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP 6
HBD3 DEFB103 GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK 11
HBD4 DEFB104 ELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRKWDESLLNRTKP 7
Sequences are in single letter code and conserved cysteines are highlighted. DEFB4, DEFB103, and DEFB104 are on the hyper-copy number variable gene cluster in the human
genome chr 8p and termed A or B in ensemble to distinguish their independent location in the genome (25). Please note we use here the common peptides names rather than the
official designated peptide names (e.g., HBD1 instead of DEFB1etc.). Net charge at pH 7 calculated using https://pepcalc.com/.
immune or inflammatory modulators, but it is important to
bear in mind that synthetic preparation and oxidation of
defensins is not trivial. Correct cysteine disulphide bonding
and oligomerisation may have an important effect on function
as has been shown for the chemoattractive role of defensins
(40). In some cases, recombinant peptides have been used,
which poses some concern regarding contamination with
Lipopolysaccharide (LPS). Some β-defensins are highly charged
molecules and their structure in vivo can be monomeric or
dimeric, oxidised or reduced, depending on the tissue, with
known effects on both antimicrobial and other function(s)
(40–43). In addition, apart from the reproductive tract, where
expression is strong and constitutive, β-defensins are generally
expressed at very low levels until induced by inflammatory
mediators. The concentration of peptide used in in vitro
experiments is therefore likely crucial to determine the true
in vivo effect. Thus, studies using peptides in vitro are
important, but may not always reflect physiological functional
relevance. With those consideration in mind, we discuss
below the evidence for β-defensins as host defence peptides,
able to modulate the immune system in various ways (see
Figure 1).
BETA-DEFENSINS AS ALARMINS
Alarmin is a term first coined by Yang and Oppenheim,
for endogenous molecules that act as signals for tissue and
cell damage (45). They are characterised by a number of
central principles, which include the ability to recruit and
activate innate immune cells, and bridge to and/or promote
adaptive immune responses, whether through direct or indirect
mechanisms (46, 47). Increasingly, β-defensins are shown to be
involved in pathways of this type, acting as both chemokines
for adaptive immune cells and as innate immune stimuli
(detailed below). This is suggestive of an alarmin role for
these peptides.
Chemokines
Both β and α-defensins can act as chemoattractants for immune
cells (see Figure 1). Some years ago the similarity of defensin
structure to chemokines was noted, alongside recognition
that many chemokines can have antimicrobial activity under
similar experimental conditions to those under which defensins
were studied (48, 49). In addition, similarly to chemokines,
defensins bind glycosaminoglycans (GAG) and oligomerise
(50). Various human β-defensins can attract immune cells
including immature dendritic cells, memory CD4+ T cells,
monocytes, and activated neutrophils at low (∼10–100 ng/ml)
concentrations, similar to known chemokines (∼0.02µM) (40,
51, 52). When this chemoattractant ability was first described,
it was a very exciting observation, revealing defensins as a
bridge between the innate response and adaptive immune cell
recruitment. CCR6 (receptor for CCL20) was identified as a
receptor through which defensins could mediate chemotaxis
of lymphocytes and neutrophils, with structural similarities to
CCL20 being detected (51–53). However, it was also shown
that an as yet unidentified receptor, independent of CCR6,
could mediate chemoattraction of CD4+ T cells and dendritic
cells by a murine β-defensin (54). In addition, monocytes were
shown to be attracted by HBD3 and this activity was shown
to be dependent on the cysteine stabilised structure, whereas
antibacterial activity was not (40). Interestingly, restoration
of a single cysteine (cysV) was sufficient to enable human
monocyte chemoattractant activity for HBD3 and its mouse
orthologue Defb14 (55). Of physiological relevance, in vivo
studies only found evidence for the HBD2-mediated attraction of
macrophages (and not dendritic cells) following intraperitoneal
injection of mice with the peptide (54, 56). Subsequently,
CCR2 was shown to be a macrophage receptor through
which HBD3 (and Defb14) could induce monocyte/macrophage
cell movement (57). Indeed, HBD3 expression has been
suggested to result in tumour associated macrophage attraction
in vivo through CCR2 (58). In addition, HBD1, 2, and
4 can all have their expression increased by 1Np63 in
normal and squamous cell carcinomas and exert a chemotactic
activity for (lymphatic) endothelial cells in a CCR6-dependent
manner (59).
In addition to these direct chemoattractant properties,
defensins can also function indirectly by inducing chemokine
expression. Human keratinocytes exposed to a high
concentration (30µg/ml; ∼6µM) of HBD-2, -3, or -4, increase
the gene expression and protein production of IL-6, IL-10,
IP-10, CCL2, CCL20, and RANTES. The treated cells displayed
enhanced Ca2+ mobilization, chemoattraction, proliferation and
phosphorylation of epidermal growth factor receptor (EGFR);
signal transducer and activator of transcription (STAT)1, and
STAT3 (60). This pro-inflammatory response was markedly
suppressed by G protein coupled receptor inhibitors.
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FIGURE 1 | The many roles of β-defensins. β-defensins have been shown to have a wide range of roles, that go far beyond basic antimicrobial activity. These can
loosely be grouped into five key groups; triggering and enhancing, chemoattraction (chemoattractive), neutral antagonist, non-resolving and resolving. These functions
are represented here, alongside the most prominent cell types/tissues/organisms associated with that particular role. Particular receptors that are known be involved
in these pathways have also been highlighted, alongside the consequence of the β-defensin stimulus. These have also been grouped into pro-inflammatory or
anti-inflammatory (or neither). Abbreviations: interferon (IFN), toll like receptor (TLR), Dendritic Cell (DC), interleukin (IL), T helper (Th), regulatory B cell (Breg).
β-defensin structure taken from PBD reference 1kj6 (44).
Innate Triggers
In addition to acting to promote chemotaxis of a range of
immune cells, the β-defensins have a range of other modulatory
functions that expand their repertoire beyond simplistic
microbicidal activity (see Figure 1). A proinflammatory
response to HBD3 was observed in monocytes, when a robust
concentration of 3.8µM (20µg/ml) was used to induce an
increase in co-stimulatory molecules CD80, CD86m and CD40
and proinflammatory cytokines in a TLR1/2 dependent manner
(61). However, unlike TLR2 ligands, HBD3 did not increase
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levels of IL-10 and did not reduce co-stimulatory molecule
expression (62). At 1µM (5µg/ml) HBD3, we see no evidence
of proinflammatory responses in primary macrophages. At
5µM and above, HBD3 can cause membrane damage in
monocytes (but not B and T cells) through interaction with the
negatively charged phospholipids (63), thus care is required to
consider the concentrations at which cellular stress responses
to supraphysiological conditions might occur. HBD3-mediated
CD86 expression (but not CD80) was shown to be induced
via the ATP-gated channel P2X7 (64). Similarly, recombinant
mouse β-defensin 2 (Defb2 peptide) was shown to induce
maturation of dendritic cells via TLR4, proposing it as a potential
adjuvant, although this was only observed with a fusion protein
incorporating this peptide, and not with peptide alone (65).
Innate Enhancement
In addition to these stimulatory effects of antigen presenting
cells, defensins have been shown to alter cellular processing,
and inflammatory responses to DNA and RNA. In plasmacytoid
dendritic cells (pDC), enhanced intracellular uptake of CpG
or self-DNA was observed when the DNA was associated with
either HBD3 or HBD2 at a 1:2µM ratio, thus promoting TLR9-
dependent IFN-α production in both human and mouse (66, 67).
This was also observed with bacterial DNA in human and mouse
pDC, but a response to self-DNA was only seen in the human
cells (68). It is likely that these observed increases in ligand uptake
and TLR9 signalling are due to the ability of these cell-penetrating
peptides to increase the transport of the DNA into the cells (69).
However, HBD3 is also able to oligomerise and may increase the
ability of the DNA to interact with TLR9 effectively. This has
been shown for HBD3 and another cationic host defence peptide
cathelicidin, LL-37, as well as other cationic peptides. Schmidt
et al. (70) elegantly showed that the peptides can form columnar
nanocrystalline complexes with dsDNA and that the distance
between the DNA columns influence a stronger or weaker
interaction with the TLR9 receptor, which signals to produce
type I interferon (71). Importantly these effects have also been
observed in vivo, with intravenous injection of mice with CpG
DNA:HBD3 complexes generating increased IL-6, IFN-γ, IL-
12p70, IL-10, and IFN-α in the serum 24 h later when compared
to CpG DNA alone, and an increase in antigen presenting cells in
the spleen (66).
In addition, primary mouse macrophages, when pre-
stimulated for 4 h with a fusion protein of IgG1 and the mouse
orthologue of HBD3, Defb14, then subsequently stimulated for
24 h with endosomal (TLR3 and TLR9) or heterodimer (TLR1/2)
ligands, showed an increase in proinflammatory cytokines and
chemokine CXCL12, independent of the presence of CCR2 or
CCR6 (72). The Defb14 fusion did not induce a cytokine signal
on its own. These studies reveal a complex interplay with other
factors, via which these defensins may contribute to enhanced
adaptive responses.
Our lab has shown that the presence of HBD3 alters innate
signalling to double stranded RNA poly I:C, increasing the
Interferon-β (IFNβ) response and decreasing CXCL10 (IP10)
production in vivo and in vitro in both mouse and human
primarymacrophages (73). PolyI:C is a synthetic double stranded
RNA (dsRNA) and consequently acts as a mimic of virus or
product of damaged cells. It is recognised by endosomally
located TLR3 and also by cytoplasmic RIG-I-like receptors
(RLRs). High molecular weight (HMW) poly I:C preferentially
signals through the RLR MDA5 (Melanoma Differentiation-
Associated protein 5), also known as IFIH1 (interferon induced
with helicase C domain 1) and produces Interferon β (IFNβ).
We showed that 0.1µM HBD3 enhanced poly I:C-mediated
MAVS (IPS-1) and MDA5 signalling, increasing IFNβ, but
decreased TLR3 stimulation and CXCL10 signalling (72) in
primary murine macrophages. The peptide rapidly entered
the macrophages (within 10min), decreased the endosomal
localisation of the HMW PolyI:C and increased cytoplasmic
localisation. This contrasted with the effect of the cationic lipid
lipofectamine on HMW PolyI:C, which increased endosomal
signalling through TLR3. LL-37, a cathelicidin cationic AMP
with some similar immunomodulatory actions to HBD3 (74),
can also increase dsRNA induced signalling through MAVS and
TLR3 to increase production of proinflammatory cytokines and
IFNβ in keratinocytes (75). For TLR3 this is partially due to
the alpha helical LL-37 peptide forming crystalline structures
with dsRNA which matches the steric size of TLR3, allowing
recruitment and engagement of multiple TLR3 receptors and
an increased cytokine signalling response (76) in a similar way
to peptide-induced DNA association with TLR9. The increased
signalling by MDA5 in the presence of HBD3 and HMW polyI:C
might also be structurally dependent. Of note, linear HBD3
peptide does not increase IFNβ production and MDA5 normally
forms filaments around dsRNA for oligomerization; we therefore
speculate that this may be optimised in the presence of correctly-
folded HBD3 (77).
The properties of other immune cells can also be modified
by exposure to defensins, to promote host defence mechanisms.
In the presence of HBD3, human NK cells increase CD69
C-Type lectin protein expression and secrete IFNγ, killing the
NK sensitive myeloid cell line K562. In addition, HBD3 can
function through the Mas related gene X2 to activate and
initiate degranulation of mast cells (78, 79). Other cationic
amphipathic peptides, such as LL-37, have also been shown to
have this capacity.
Finally, defensins may modulate cell death, with possible
consequences for inflammation. β-defensins have been shown
to downregulate the pro-apoptotic truncated protein Bid and
upregulate the anti-apoptotic Bcl-xL, leading to inhibition
of mitochondrial membrane potential change and decreased
caspase 3 activity and apoptosis (80). HBD3 is the most potent
of the human β-defensins in this regard. Neutrophil apoptosis
is important in resolution of tissue damage, thus limiting
apoptosis may also be pro-inflammatory. In contrast, in human
airway smooth muscle cells, the addition of HBD3 (at high
concentrations of 5 or 10µM) has been shown to induce CCR6-
dependent production of IL-8 and cell apoptosis. This apoptotic
effect appeared to be induced by ERK1/2 MAPK and ROS-
induction (37). This may be important context for scenarios
in which higher concentrations of the peptide are seen to be
inflammatory and leading to cytotoxic effects. Cytotoxicity has
been seen for high concentrations of HBD3 (over 20µM) in
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a wide variety of cells in culture, including DC, normal and
immortalised keratinocytes and primary oral gingival epithelial
cells (81).
Receptor Neutral Antagonism
There are several examples of defensins acting as promiscuous
ligands for receptors (see Figure 1) helping to explain
the pleiotropic properties observed. This may be due to
complementary electrostatic interaction between the cationic
peptide and receptors with anionic regions. HBD3, the
most highly charged β-defensin (charge of +11) has been
demonstrated to be a neutral antagonist, through charge based
interaction with melanocortin receptor 1 and 4 (82). In dogs,
a three base pair deletion in the canine orthologue of HBD3
results in an increase in the level of expression, which then
allows this peptide to promiscuously bind the melanocortin
receptor 1 (MC1R)—resulting in dogs with black, rather than
agouti, fur (83). When the mutant or wildtype dog genes are
expressed ubiquitously in transgenic mice, under a powerful
promoter, their coat colour is also black (despite being genetically
agouti). This demonstrates that an inappropriately high, level
of β-defensin can result in promiscuous receptor binding in
vivo. A further example of promiscuous receptor binding and
neutral antagonist behaviour is the ability of recombinant HBD3
(at 5, 10, 20, and 40µg/ml) to compete with stromal-derived
factor 1 (SDF-1), in a structural and charge dependent manner,
for cellular binding to CXCR4, without increasing calcium
mobilization or chemotaxis (84, 85). CXCR4, also known as
fusin, is used for HIV entry into CD4+ T cells. However, copy
number increase of the HBD3 gene does not associate with
protection against HIV (86).
BETA-DEFENSINS AS RESOLVERS
In contrast to alarmin activity (see section Beta-Defensins as
Alarmins) we use the term “resolvers” here to describe the anti-
inflammatory pro-resolving activity of β-defensins.
Innate Suppression
As discussed above, in the presence of defensins, some pattern
recognition receptors increase the response to stimulation.
However, exposure to TLR4 ligands (such as LPS) or CD40
activation in the presence of HBD3 (1µM) results in a decrease
in cytokine responses in primary macrophages (87, 88). This
anti-inflammatory effect was also observed in vivo, where serum
from mice displayed a decrease in proinflammatory cytokines
following injection of LPS and HBD3 peptide compared to
LPS alone (87). This suppression was independent of defensin
binding to TLR4 or LPS and could be observed even if
the peptide was added up to an hour after the LPS. HBD3
suppressed cytokine and type I interferon production through
the MyD88 and TICAM1 pathways, respectively (89). Exposure
to HBD3 and LPS compared to LPS alone showed reduced
transcription of many genes associated with TLR4 activation,
while others were increased, including TLR2—demonstrating
that this was not simply an inhibition of all signalling
downstream of the receptor. HBD3 alone had no effect on
macrophage transcription. Further pathway analysis, using
InnateDB, showed that many LPS-induced proinflammatory
signalling pathways were downregulated when HBD3 was also
present but that metabolism, classical complement activation and
FcγR-dependent phagocytosis were upregulated (74). The anti-
inflammatory effect of HBD3 on macrophages was also seen
in the acute inflammatory cytokine response to Porphyromonas
gingivalis in vitro and in vivo (88). Indeed, mice with an
exaggerated response to P. gingivalis LPS (ApoE –/–) showed
an increase in CCL2, TNF-α, IL-6, and NO levels at 2 h—
but HBD3 (10 µg/mouse) could suppress this. The authors
also report an increase in Arginase 1, a key marker of
mouse alternatively activated macrophages (AMM or termed
M2), possibly indicating a change in cellular polarisation as a
consequence of defensin exposure.
A similar inflammation suppressive effect has also been
recently observed with HBD2, which reduced TNFα and IL-
1β secretion from dendritic cells in human peripheral blood
mononuclear cells exposed to LPS. The effect was lost in the
presence of a CCR2 inhibitor. When HBD2 was delivered
systemically to a variety of mouse models of inflammatory
bowel disease, the colitis was reduced to a level comparable to
steroids and anti-TNFα (90). In addition, in the infected cornea
of mice, silencing of the murine orthologues of HBD2 and 3
resulted in increased production of proinflammatory cytokines,
with a simultaneous increase in bacterial load (91). The effect
on bacterial load is postulated to be due to the defensins [at
low concentration of 1µg/ml (0.2µM)] inhibiting macrophage
autophagy and in this way increasing phagocytic receptor
expression leading to intracellular killing of the Pseudomonas
aeruginosa (92). All these studies indicate that, under specific
infections scenarios, defensins are capable of contributing to anti-
inflammatory response, or at least a rebalancing of the nature of
the cellular response.
Adaptive Suppression
In addition to effects on innate responses to infectious and
inflammatory stimuli, defensins have also been shown to have
suppressive effects on adaptive immunity. UVB radiation induces
Defb14 production in keratinocytes while DEFB14 peptide
injection into mice suppressed contact hypersensitivity, but
this was shown to involve the induction of antigen-specific
regulatory T cells (Tregs), rather than the UV suppression
pathway (93). The HBD3 peptide [at 10µg/ml (2µM)] has
a demonstrated capacity to alter CD4+ CD25- T cells, from
a non-regulatory phenotype towards a regulatory phenotype
with expression of both the characteristic regulatory T cell
(Treg) transcription factor (FoxP3) and cytotoxic T-lymphocyte-
associated protein 4 (CTLA4), a protein which downregulates
immune responses (94). Treatment of CD4+CD25– cells
with DEFB14 resulted in reduction in methylation of the
Foxp3 promoter compared to cells without DEFB14 (and
closer to the level seen in Tregs) which correlated with
an increase in FoxP3 expression. Additionally, treatment
with DEFB14 before, or after, the induction of experimental
autoimmune encephalomyelitis (mouse model of multiple
sclerosis), was found to ameliorate the disease, with less
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central nervous system inflammation and decreased levels of
proinflammatory cytokines and cytotoxic T cells (94). The
beneficial effect was lost upon depletion of regulatory T
cells. These observations were attributable to an increase in
suppressive CD4+ T cells, possibly through a change in cellular
polarisation but the mechanism underpinning defensin-induced
modulation of CD4+ T cells to a regulatory phenotype requires
further investigation.
Further evidence of immune suppression by HBD3 (or
DEFB14) arises from studies of diabetes. β-defensins were shown
to be expressed in endocrine cells in both the human and
mouse pancreas (95). DEFB14 treatment of non-obese diabetic
mice was found to dampen the autoimmune response and to
reduce subsequent diabetes development. This disease limitation
was shown to be due to DEFB14 increasing proliferation of
pancreatic B cells, expressing the regulatory cytokine IL-4 and
the repair cytokine active TGFβ, which enabled polarisation of
alternatively activated macrophages and a subsequent increase
in Treg cells. This immune modulating pathway was believed
to account for the reduction in autoimmune inflammation, with
DEFB14 playing an integral role possibly through induction
of TLR2.
Wound Healing Resolution
In addition to roles in innate and adaptive immune responses,
β-defensins have been found to play important roles in
resolution of damage pathways, via effects on wound healing.
Characterising chronic wounds, β-defensin expression is found
to be decreased in diabetic ulcers (96). This is thought to
contribute to increased infection and also to a lack of wound
healing, through mechanisms such as stimulating the migration
of fibroblasts, as well as the proliferation of keratinocytes (97, 98).
HBD2 also is reported to promote wound healing of intestinal
cells in vitro (99) and in vivo by stimulating keratinocyte
migration and proliferation in rats (100). The physiological
significance of these findings are demonstrated in mice with
Defb14 deletion, which display delayed wound healing in vivo,
with significantly increased wound area, delayed epithelialisation
and an altered wound microbiota (97). In addition, there is
an observed increase in classically activated macrophages in
these wound sites and a trend towards decreased alternatively
activated macrophages, together with an increased bacterial
load in the skin (97). This implies that DEFB14 is important
in wound repair and that insufficient peptide expression may
reduce wound healing as a consequence of inappropriate
macrophage polarisation (section Innate Suppression) and/or
alteration in the ratio of local cellular populations. Macrophages
are key in wound repair and can be central in the process by
promoting a resolution of inflammation leading to tissue repair.
CCL2, the major macrophage chemoattractant, can reverse the
impaired wound healing in diabetic mice (101) and HBD3 can
chemoattract macrophages through CCR2 and also modulate
pattern recognition receptors relevant to wound repair (102,
103). As with all resolution milieu, successful wound healing will
bemultifactorial, but these data suggest that β-defensins are likely
to contribute.
HUMAN DISEASE ASSOCIATION
Given the range of roles that β-defensins display, it is not
surprising that their expression and influence are demonstrably
intertwined into various disease states. For the sake of
examining β-defensins in human non-infectious disease,
however, discussion will be based on the main expression sites,
epithelial cells, predominantly localised to the gut and skin.
We will not be addressing their influence on cancer, although
the involvement of β-defensins in cancer also demonstrates
dichotomous behaviour. For example, their expression can
be increased or decreased in tumours, their influence can be
to promote or suppress, and these effects can be dependent
upon the specific defensin peptide, the cancer type and the
cells involved [for an excellent, recent review of the literature
see (104)].
In addition to the complex, localised environmental influences
that dictate β-defensin function, there is the issue of copy number
variation, as mentioned previously. Six β-defensin genes (DEFB4,
DEFB103, DEFB104, DEFB105, DEFB106, DEFB107), and the
β-defensin related gene SPAG11, are present at chromosome
8p23.1, at two loci 5Mb apart and are hyper CNV, changing
through unequal crossing over at the rate of ∼0.7% per gamete
(25). Worldwide, the average copy number of this unit is four,
although copy numbers range from two to twelve (this does
not occur in all species, with mice being an example of no
copy number variation). The variation in these genes, combined
with the alteration in expression based on localised stimulation,
gives a large range of expression for these peptides, with overall
inflammation in disease considered a stronger influence on
expression than copy number (5, 105). The link between the level
of expression of β-defensins and disease is discussed below.
Psoriasis
Indication that β-defensin copy number associates with disease
development is evident in psoriasis. Psoriasis is a disease
principally characterized by skin plaques, commonly found on
the elbows, knees and trunk. Psoriatic lesions are described as
sites of chronic skin inflammation with thickened, hyperplastic
epidermis, increased vascularity and immune cell invasion.
Lesions display overexpression of several inflammatory peptides
and cytokines. The overexpression of these local cytokines (such
as TNFα, IFNγ and IL-1) leads to increased expression of β-
defensins within the lesions (106, 107), to a degree that allowed
both HBD2 and HBD3 to be first isolated from psoriatic scales.
In addition, there is a significant, replicated association between
more than four copy numbers of the β-defensin seven gene
repeat unit and psoriasis occurrence (108, 109). This goes beyond
localised disease region expression, however, as serum levels of
HBD2 correlate with copy number, both in normal individuals
and disease state (where increase in serum HBD2 also correlates
with psoriasis severity) (110) and HBD3 expression is increased
in both normal and lesional skin of psoriasis patients, possibly
adding to the reduced bacterial burdens in lesions compared
with those in atopic dermatitis (see below) (111). It is not
clear how increased β-defensin expression contributes to disease
aetiology, but, as mentioned above, β-defensins HBD3 and 2 have
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FIGURE 2 | The possible implications for β-defensins in psoriasis. Psoriasis is a disease characterised by scaly lesions, hyperplastic epidermal thickening, immune cell
accumulation and is triggered by some sort of insult to the skin. HBD2 and 3 may contribute to the disease process as a consequence of increased gene copy
number increasing the level of the peptide response to inflammation and enhancing monocyte/macrophage recruitment and increasing uptake of nucleic acids
released from dying cells or microbes at the site of damage. Shown here is increased dsRNA entering macrophages with β-defensin and enhancing IFNβ secretion
leading to Langerhan cell maturation and interleukin (IL)-23 release to influence mature T cell polarisation to T helper (Th)17. IL-22 production from Th17 may then
further stimulate β-defensin production and amplify the process. Abbreviations: Copy number (CN), C-C chemokine receptor type 2 (CCR2), interleukin (IL), melanoma
differentiation-associated protein 5 (MDA5), T helper (Th).
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been shown to increase the Interferon-α response to DNA via
TLR9 and the Interferon-β response to RNA through stimulation
of the MDA5/MAVS pathway (see section Innate Triggers).
HBD2 has been shown to be evident in the same dermal
compartment as pDC in psoriatic skin, leading to a hypothesis
that this peptide may be instrumental in breaking tolerance
to self-DNA following infection or damage (67). Injection
of CpG DNA:HBD3-defensin complexes subcutaneously in
mice, increased epidermal hyperplasia and both neutrophil and
lymphocyte recruitment at 24 h (66), supporting this hypothesis.
Psoriasis is a Th17 predominated disease and effective treatment
with UV irradiation is linked to suppression of type I Interferon
and Th17 cells (112). In addition, psoriasis can be induced
in multiple sclerosis patients using IFNβ therapy (113). The
current effective treatments for psoriasis are biologics against
IL-17 production or IL-12p40 (subunit common to both Il-
12 and IL-23), to limit Th17 cell production and action.
Of note, IL-22 is expressed by Th17 cells, which triggers β-
defensin expression (95). Interestingly, individuals with missense
variants in Human MDA5 gene (IFIH1) are protected from
psoriasis (114) and gain of function MDA5 mutations have
related type I interferonopathy with musculoskeletal disease
that includes psoriasis (115). These lines of evidence strongly
support the involvement of Interferon β in psoriasis and the
genetic link between increased β-defensin CNV and psoriasis
may be due to an increase in β-defensin expression having a
functional consequence in the responses to dsRNA released from
wounds, via MDA5/MAVS signalling and production of IFNβ
(see Figure 2).
Atopic Dermatitis
Another skin disease associated with β-defensin expression is
atopic dermatitis (AD) [for a more extensive review of the
associations between β-defensin and AD see Chieosilapatham
et al. (116)]. AD is another chronic inflammatory skin disease,
characterised by itchy, inflamed lesions across a range of different
body sites (117). In comparison with psoriatic plaques, AD
lesions have a decrease in expression of these β-defensins (118)
with induction of peptide levels found to be impaired for the
level of inflammation. This has not been found to be related
to copy number variation, however, and is instead due to the
local Th2-skewed cytokine milieu and thus focused inhibition of
β-defensin expression (119). Despite these lesional differences,
HBD2, but not HBD3, is found to be increased in AD serum
(120). Reduced defensins at the sites of disease may contribute
to the pathology of AD in a number of ways, including the
increase in lesional skin infections that are characteristic of
the condition (121) (see Figure 3). In addition to the direct
bactericidal properties of some of these peptides, it has been
shown that HBD3 can increase expression of tight junction
components in keratinocytes and improve barrier function (122).
Further, we recently demonstrated that some β-defensins, such
as HBD2, are able to inhibit the barrier-damaging effects of
bacterial proteases, such as from the common AD lesional
pathogen Staphylococcus aureus, which can contribute to this
disease, in which loss of barrier integrity is critical (123). The
mechanism of this is not yet fully elucidated and is subject to
further investigation.
Inflammatory Bowel Disease
In addition to inflammatory disorders of the skin, β-defensin
expression has been shown to be altered in chronic inflammatory
disorders of the gut. Unlike the skin, however, β-defensins are not
the key AMP type in the gastrointestinal tract. Instead, the most
abundantly expressed AMP group is the human α-defensins,
including human defensin 5 (HD5) and human defensin 6
(HD6), which are constitutively expressed by Paneth cells located
at the base of the crypts of Luberkühn (unique to the small
intestine) (124, 125). As well as being known to have antibacterial
(HD5) and antiviral (HD6) activities (126), these peptides are
known to be chemoattractive for naïve and memory CD4+
T lymphocytes, as well as macrophages and mast cells (127).
Similarly to their β-defensin cousins, they are also linked chronic
inflammatory disorders, with decreased levels of both HD5 and
HD6 being demonstrated in ileal Crohn’s disease (affecting the
upper parts of the intestine) (128). It is thought that this lack of
expression allows for increased pathogenic bacteria and therefore
worsening of pathology (129).
While α-defensin are present in Paneth cell granules in
the upper parts of the intestine, β-defensin expression is
conducted by enterocytes, which are the most abundant
epithelial cell lineage in both the small and large intestine
(130). Enterocytes of the colon express HBD1 constitutively,
with HBD2 being induced by TLR stimulation (131). HBDs
can also be induced in the gastric mucosa, when faced with
bacterial challenge (132) and expression of β-defensins is
shown to be altered in chronic inflammatory bowel diseases
(IBD) of the gut. Comparably to the relationship between β-
defensin levels and different chronic inflammatory disorders
of the skin, there appears to be a discrepancy in activity
in different IBD disorders of the gut. Patients who suffer
from Crohn’s disease present a decrease in HBD2 β-defensin
levels, and a concomitant decrease in the gene copy repeating
unit suggested as a factor for predisposition to the disease
(133, 134). HBD2 has recently been delivered subcutaneously
to mice with induced models of intestinal bowel disease
and successfully reduced the level of inflammation (90). In
opposition to Crohn’s disease, patients with ulcerative colitis
(a disease of the colon) have a highly increased expression of
HBD2, although not HBD1 (135). This has been argued to
be due to changes in localised cytokine milieu, rather than
variations in copy number. Aldhous et al. demonstrate that
DEFB4mRNA and HBD2 protein levels varied upon stimulation
with inflammatory cytokines in samples from IBD patients,
independent of variations in HBD2 copy number (105). In this
case, the influence of copy number variation is overridden by
the impact of the local inflammatory environment. However,
this is in the context of the high level of variation in defensin
expression from one region of the gut to another, which is also
in combination with differences between biopsy location and
inflamed vs. non-inflamed areas of the bowel (105). This requires
further study and the influence of the microbiota on defensin
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FIGURE 3 | The possible implications for β-defensins in atopic dermatitis. Atopic dermatitis (AD) is a chronic, relapsing disease associated with itchy lesions on the
skin, across a large proportion of the body. These lesions are characterised by a breakdown in the barrier function of the uppermost regions of the skin (the
epidermis). This allows for an increase in bacterial infection, which is made worse by bacterial production of proteases that further breakdown the junctions between
cells, as is the case for V8 (SspA) production by Staphylococcus aureus. In AD, there is a downregulation in a number of Th1-associated cytokines, such as Tumour
Necrosis Factor (TNF)α and interleukin (IL)-1β, as well as antimicrobial peptides, such as the β-defensins (including HBD2). It is thought that the AD-associated,
localised cytokine milieu, which has a T helper (Th)2-skewed phenotype, is responsible for this reduction. Inhibition of the induction of β-defensins prevents proper
bacterial removal/inhibition, worsening infection and AD pathology. Abbreviations: interleukin (IL), Toll Like Receptor (TLR), pathogen recognition receptor (PRR).
expression and defensin expression on microbiota composition
needs clarification.
CONCLUSION
It is clear that β-defensins are not only AMPs, and their ability
to change the behaviour of eukaryotic (particularly immune)
cells at similar concentrations as those required to kill pathogens
is intriguing. Here we have described the increasing body of
research that has revealed the ability of β-defensins to behave
in a dichotomous way with respect to inflammation. Under
certain conditions they behave as alarmins and yet under other
conditions they are suppressors of inflammation. The difference
in effect does not seem to be due to the levels of peptide.
As the Dorin lab has shown, the same peptide preparation
Frontiers in Immunology | www.frontiersin.org 10 June 2020 | Volume 11 | Article 1176
Shelley et al. Dichotomous Responses of β-Defensins
on human and mouse primary macrophages can suppress or
increase inflammatory signalling, dependent on which PRR
ligand is used. The charged nature of β-defensins is likely to
be important in how it interacts with a variety of molecules
and may explain why HBD3, with its high charge, consistently
gives the most potent responses. Blocking receptors, binding
to nucleic acids to enhance receptor engagement, and inducing
chemoattraction, are all likely to be driven by the cationic and
amphipathic nature of the peptides. At higher levels (above
2µM) β-defensins certainly have a cytotoxic effect, but this may
be supraphysiological. During infection, rapid killing, detection
and innate response are essential; therefore, in this regard, high
HBD3 copy number and potentiation of PRR may be beneficial.
However, an undesirable effect of increased copy number of
the defensin cluster (and concomitant increase in expression of
defensin peptides) may be over stimulation of PRRs leading to
exuberant production of type I interferons. This double-edged
sword may provide protection against pathogens in the short
term, but in the longer term contribute to the development of
psoriasis in individuals with an increased copy number of the
β-defensin cluster.
In vivo experiments are the most compelling to attribute
function, because other cationic host defence peptides will also
play a part, as some have synergistic actions and come from
recruited, as well as resident cells at the site of injury. The in vivo
evidence that DEFB14 or HBD3 can increase the inflammatory
state of mouse skin but increase wound healing and suppress
development of autoimmune diabetes are clear demonstrations
of the dichotomy of the influence of β-defensins on mammalian
cells. The influence of increased β-defensin expression in
psoriasis and reduced expression in atopic dermatitis may reflect
the different disease environments; in this case increased copy
number in psoriasis may be the causative factor. This is an
exciting area of research and further clarification of the factors
that give rise to the type of response β-defensins encourage is
important for therapeutic strategies.
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